Gilead's Yescarta Label Update Approved by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2025
0mins
Should l Buy GILD?
Gilead Sciences Inc's stock rose 4.01% as it reached a 52-week high, reflecting positive market conditions.
The FDA has approved an update to Yescarta's prescribing information, removing limitations for use in patients with relapsed or refractory primary central nervous system lymphoma. This significant advancement is based on positive results from a Phase 1 study conducted by Dana-Farber Cancer Institute, which emphasizes Yescarta's unique position in this therapeutic area. The approval addresses urgent clinical needs, potentially improving survival outcomes for patients with a five-year survival rate of only 30%.
This FDA approval not only enhances Gilead's product offerings but also reinforces its competitive position in the oncology market, likely boosting investor confidence and market interest in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 146.630
Low
105.00
Averages
137.88
High
154.00
Current: 146.630
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Sciences Stock Rises Ahead of Positive Earnings Outlook
- Stock Performance: Gilead Sciences (GILD) closed at $146.63, up 1.88% from the previous session, outperforming the S&P 500's 0.83% gain, indicating strong market confidence in its future performance.
- Earnings Expectations: The company is forecasted to report an EPS of $1.86, reflecting a 2.76% increase from the same quarter last year, with expected revenue of $6.86 billion, a 2.93% rise, showcasing stability in its HIV and hepatitis C drug sectors.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Gilead's EPS estimate has increased by 0.59% over the past 30 days, suggesting analysts' favorable outlook on the company's health and profitability, which could positively influence stock prices.
- Valuation Analysis: Gilead's forward P/E ratio stands at 16.62, below the industry average of 19.76, indicating its stock may be undervalued, while a PEG ratio of 1.89 suggests strong future earnings growth potential, likely attracting more investor interest.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Three Blue-Chip Stocks Designed for a Shifting Market
Sector Rotation: Investors are moving funds from overvalued sectors, particularly tech, into undervalued sectors like energy and consumer staples, as they seek stability in a rotating market.
Duke Energy: Duke Energy is highlighted as a strong investment option due to its stable dividend yield of around 3.2% and its focus on diverse energy sources, positioning it well for future growth.
Gilead Sciences: Gilead is recognized for its defensive growth potential in the biotech sector, with strong performance in HIV therapies and upcoming product launches expected to drive revenue growth.
Hershey Company: Hershey's stock has seen significant gains, breaking out of a bearish trend, and analysts forecast strong earnings growth, making it a recommended buy in the consumer staples sector.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
Analysis of QQQM ETF's 52-Week Price Fluctuations
- Price Range Analysis: QQQM ETF's 52-week low is $165.72 per share, with a high of $262.2342, while the last trade was at $248.42, indicating stability near the high point which may attract investors looking for pullback opportunities.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, thus impacting the underlying holdings and reflecting market supply and demand changes.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market sentiment.
See More
Stock Futures Plunge as Jefferies Faces Lawsuit Over $126.4M Claim
- Jefferies Lawsuit Crisis: Jefferies Financial faces a lawsuit from Western Alliance Bancorporation for allegedly failing to pay $126.4 million under a forbearance agreement, resulting in a 2% drop in premarket trading, which could undermine its market credibility and future financing capabilities.
- Trade Desk Downgrade: Wedbush downgraded Trade Desk's investment rating from 'neutral' to 'underperform', citing an overestimation of the positive impact from the rumored OpenAI deal, leading to a 1.98% decline in premarket shares, potentially affecting its future investment appeal.
- Nike Restructuring Costs: Nike expects to incur approximately $300 million in pretax charges related to employee severance over the next nine months, with a 0.36% drop in premarket trading, indicating short-term financial pressure as the company seeks to enhance operational efficiency and profitability.
- Gilead Negotiations with South Africa: Gilead Sciences saw a 1% decline in premarket trading amid discussions with South Africa regarding local production of its HIV therapy lenacapavir, a move that could impact Gilead's market share and supply chain in the region.
See More
Gilead Sciences Stock Rises Ahead of Positive Earnings Outlook
- Stock Performance: Gilead Sciences (GILD) closed at $146.63, up 1.88% from the previous session, outperforming the S&P 500's 0.83% gain, indicating strong market confidence in its future performance.
- Earnings Expectations: The company is forecasted to report an EPS of $1.86, reflecting a 2.76% increase from the same quarter last year, with expected revenue of $6.86 billion, a 2.93% rise, showcasing stability in its HIV and hepatitis C drug sectors.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Gilead's EPS estimate has increased by 0.59% over the past 30 days, suggesting analysts' favorable outlook on the company's health and profitability, which could positively influence stock prices.
- Valuation Analysis: Gilead's forward P/E ratio stands at 16.62, below the industry average of 19.76, indicating its stock may be undervalued, while a PEG ratio of 1.89 suggests strong future earnings growth potential, likely attracting more investor interest.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Three Blue-Chip Stocks Designed for a Shifting Market
Sector Rotation: Investors are moving funds from overvalued sectors, particularly tech, into undervalued sectors like energy and consumer staples, as they seek stability in a rotating market.
Duke Energy: Duke Energy is highlighted as a strong investment option due to its stable dividend yield of around 3.2% and its focus on diverse energy sources, positioning it well for future growth.
Gilead Sciences: Gilead is recognized for its defensive growth potential in the biotech sector, with strong performance in HIV therapies and upcoming product launches expected to drive revenue growth.
Hershey Company: Hershey's stock has seen significant gains, breaking out of a bearish trend, and analysts forecast strong earnings growth, making it a recommended buy in the consumer staples sector.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
Analysis of QQQM ETF's 52-Week Price Fluctuations
- Price Range Analysis: QQQM ETF's 52-week low is $165.72 per share, with a high of $262.2342, while the last trade was at $248.42, indicating stability near the high point which may attract investors looking for pullback opportunities.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, thus impacting the underlying holdings and reflecting market supply and demand changes.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market sentiment.
See More
Stock Futures Plunge as Jefferies Faces Lawsuit Over $126.4M Claim
- Jefferies Lawsuit Crisis: Jefferies Financial faces a lawsuit from Western Alliance Bancorporation for allegedly failing to pay $126.4 million under a forbearance agreement, resulting in a 2% drop in premarket trading, which could undermine its market credibility and future financing capabilities.
- Trade Desk Downgrade: Wedbush downgraded Trade Desk's investment rating from 'neutral' to 'underperform', citing an overestimation of the positive impact from the rumored OpenAI deal, leading to a 1.98% decline in premarket shares, potentially affecting its future investment appeal.
- Nike Restructuring Costs: Nike expects to incur approximately $300 million in pretax charges related to employee severance over the next nine months, with a 0.36% drop in premarket trading, indicating short-term financial pressure as the company seeks to enhance operational efficiency and profitability.
- Gilead Negotiations with South Africa: Gilead Sciences saw a 1% decline in premarket trading amid discussions with South Africa regarding local production of its HIV therapy lenacapavir, a move that could impact Gilead's market share and supply chain in the region.
See More
